Physician profile
Eric Heimberger
NPI 1881642510
$6,791.51
in general payments reported to CMS, 2019-2025
14 companies · $379 in 2025
The $379 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,784 · 2020: $1,992 · 2021: $124 · 2022: $117 · 2023: $152 · 2024: $244 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $775.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $2,614.25 | 2019-2025 | Real Intelligence |
| Depuy Synthes Sales INC. | $1,683.40 | 2019-2025 | Inhance, Monovisc, Orthovisc |
| Heron Therapeutics, INC. | $1,526.66 | 2020-2022 | |
| Stryker Corporation | $174.93 | 2019 | |
| Medical Device Business Services, INC. | $157.45 | 2019 | |
| Sanara Medtech INC. | $149.98 | 2020 | |
| Medacta USA, INC. | $144.87 | 2024 | |
| Zimmer Biomet Holdings, INC. | $121.25 | 2019 | |
| Medtronic, INC. | $104.93 | 2023-2025 | Kyphon Express II Kyphopak Tray |
| Vertex Pharmaceuticals Incorporated | $39.70 | 2024-2025 | |
| Solventum Corporation | $22.57 | 2024 | Prevena, V.A.C. Dermatac, V.A.C. Veraflo |
| Dynasplint Systems INC. | $19.84 | 2025 | Dynasplint |
| Wound Management Technologies, INC | $17.57 | 2019 | |
| Lemaitre Vascular, INC. | $14.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Heimberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.